MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to common...
-$11,917,015
Net loss
attributable to...
-$360,177
Net loss
-$12,277,192
Change in fair value of
derivative liabilities
$1,098,055
Revenues
$1,363,045
Gain (loss) on
extinguishment of debt
$159,035
Interest income
$116,495
Gain on forfeiture of
customer deposit
$115,000
Unrealized gain on
marketable securities
$76,596
Other income
(expense), net
$7,004
Loss before income
taxes
-$12,277,192
Total other income
(expense), net
$766,306
Total sales
$1,363,045
Amortization of debt discount
$545,635
Unrealized loss on
investments
-$163,500
Interest expense
$96,744
Loss from operations
-$13,043,498
Gross profit
$1,182,420
Cost of goods
$180,625
Total cost of
operations
$14,225,918
Professional services
expense
$7,792,100
Salary expense
$1,687,972
Research and development
expense
$1,277,150
Stock based
compensation expense
$1,215,692
General and
administrative expenses
$1,148,004
Amortization expense
$1,000,000
Selling and marketing
expense
$105,000
Back
Back
Income Statement
source: myfinsight.com
Coeptis Therapeutics Holdings, Inc. (COEPW)
Coeptis Therapeutics Holdings, Inc. (COEPW)